EUVIMEDEUVIMED entdecken
Crossref

Effect of pirfenidone on the regulation of lymph angiogenesis by PLK1 signaling to inhibit metastasis of lung cancer in vivo

Zehai Xia, Quan Wang, Lei Zheng, Qun Lv

Bioscience, Biotechnology, and Biochemistry · 23.06.2026 · 90 (7) · 877-885

DOI: 10.1093/bbb/zbag054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioscience, Biotechnology, and Biochemistry, online erschienen am 21.04.2026. Verfasst von Zehai Xia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Cell Cycle Proteins, Proto-Oncogene Proteins, Lung Neoplasms. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Clinical Medicine Special Fund Project of Zhejiang Medical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated the mechanism of pirfenidone (PFD) inhibiting the metastasis of lung cancer in vivo. A nude mouse lung cancer model was established and treated with PFD (200 and 400 mg/kg); lung metastatic tumor weight was recorded, Lyve-1 (lymphatic marker), LC3I and LC3II (autophagy protein), and polo-like kinase 1 (PLK1) were detected. In human lung lymphatic endothelial cells (HMVEC-LLy), PFD’s effects on migration, apoptosis, lymphangiogenesis, and LC3II/LC3I/PLK1 levels were tested. PLK1-overexpressed HMVEC-LLy cells were treated with 400 μg/mL PFD to explore its mechanism. PFD inhibited the weight of lung metastases and downregulated the expression levels of Lyve-1, LC3II/LC3I, and PLK1. In cell experiments, PFD was found to inhibit HMVEC-LLy migration and lymph angiogenesis, and promote apoptosis, as well as downregulate LC3II/LC3I and PLK1 protein levels, and these effects could be reversed by PLK1 overexpression. PFD may inhibit lung cancer metastasis in vivo by regulating lymphangiogenesis through PLK1 signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsLung NeoplasmsLymphangiogenesisSignal TransductionPyridonesNeovascularization, PathologicAnimalsHumansPolo-Like Kinase 1MiceApoptosisMice, NudeCell MovementCell Line, TumorEndothelial CellsLymphatic Metastasis

Stichwörter der Autor:innen

autophagylung cancerlymph angiogenesispirfenidonepolo-like kinase 1

Substanzen

Protein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsPolo-Like Kinase 1pirfenidonePyridones

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China.
  • Clinical Medical College, Hangzhou Normal University, Hangzhou, Zhejiang, China.

Förderung

  • Clinical Medicine Special Fund Project of Zhejiang Medical Association

Zitieren

APA

Xia, Z., Wang, Q., Zheng, L., & Lv, Q. (2026). Effect of pirfenidone on the regulation of lymph angiogenesis by PLK1 signaling to inhibit metastasis of lung cancer in vivo. Bioscience, Biotechnology, and Biochemistry, 90(7), 877-885. https://doi.org/10.1093/bbb/zbag054

Vancouver

Xia Z, Wang Q, Zheng L, Lv Q. Effect of pirfenidone on the regulation of lymph angiogenesis by PLK1 signaling to inhibit metastasis of lung cancer in vivo. Bioscience, Biotechnology, and Biochemistry. 2026;90(7):877-885. doi:10.1093/bbb/zbag054

BibTeX
@article{Xia2026,
  author = {Xia, Zehai and Wang, Quan and Zheng, Lei and Lv, Qun},
  title = {Effect of pirfenidone on the regulation of lymph angiogenesis by PLK1 signaling to inhibit metastasis of lung cancer in vivo},
  journal = {Bioscience, Biotechnology, and Biochemistry},
  year = {2026},
  volume = {90},
  number = {7},
  pages = {877--885},
  doi = {10.1093/bbb/zbag054}
}
Kostenlos starten →